Chief Medical Officer
Dr. Lee is an expert in oncology drug development. Working in big pharma and biotech settings, she has taken products from early clinical development to marketing approval. Most recently, she was Chief Medical Officer at BeyondSpring Pharmaceuticals, and EVP, Clinical & Medical Affairs, at Delcath Systems. Accomplishments during her 26 years in industry have included the Taxotere NDA at Rhône-Poulenc Rorer and registration-enabling clinical development of abiraterone at Cougar Biotechnology. She also worked on ibandronate at Hoffmann-La Roche, tezacitabine at Chiron, entinostat at Syndax Pharmaceuticals, GM-CSF at Sandoz, p53 gene therapy at Rhône-Poulenc Rorer Gencell, and various early-phase biologics and immunotherapy projects. Dr. Lee received her PhD from Columbia University and MD from the University of Miami. Her internal medicine residency was at Georgetown University Hospital, with a Hematology-Oncology fellowship at Fox Chase Cancer Center.